TAKEDA-PHARMACEUTICAL
Takeda Pharmaceutical Company Limited (TOKYO:4502):
FY2015: A year of turnaround to sustained growth; achieved full year management guidance | |||
• |
Underlying revenue up +3.4% (reported revenue growing +1.7% to 1,807.4 billion yen), led by strong performances in Takeda's growth drivers (GI, Oncology, CNS and Emerging Markets) |
||
• |
Underlying Core Earnings up +8.1% (reported operating profit recorded 130.8 billion yen), aided by cost discipline |
||
• |
Underlying Core EPS up +21.7% (reported EPS was 102 yen), growing 2.5x faster than underlying core earnings |
||
Growth Drivers continued to be robust | |||
• |
Consolidated underlying revenue growth of Gastroenterology (GI), Oncology, Central Nervous System (CNS) and Emerging Markets – Takeda's Growth Drivers – was +9.5% year-to-year |
||
• |
Underlying revenue of GI +23.6%, Oncology +1.0%* and CNS +37.3% year-to-year |
||
• |
Emerging Markets underlying revenue +4.8% year-to-year with continued growth in the key markets of China, Russia and Brazil |
||
*Underlying growth of Oncology excluding VELCADE royalties was +4.4% |
|||
Broad portfolio of growing products offsets loss of exclusivity decline |
|||
• |
ENTYVIO(®) is on track to exceed $2 billion MAT* sales within FY2018 |
||
• |
Encouraging uptake of NINLARO(®) and TAKECAB(®) |
||
• |
BRINTELLIX(®) and ADCETRIS(®) showed continued growth |
||
• |
AZILVA(®) and LOTRIGA(®) are contributing to the Japan business |
||
*Moving Annual Total @ constant currency |
|||
Efficiency gains continue | |||
• |
Project Summit well exceeded full-year target resulting in 30 billion yen additional cost savings |
||
• |
Strong cash flow performance with Operating Free Cash Flow, excluding Actos settlement payment, reaching 230 billion JPY |
||
FY2016 management guidance: A year of strategic focus to sustain growth | |||
• |
Underlying Revenue: Mid-single digit growth (%) |
||
• |
Underlying Core Earnings: Low- to mid-teen growth (%) |
||
• |
Underlying Core EPS: Low- to mid-teen growth (%) |
||
Christophe Weber, President and Chief Executive Officer of Takeda,
commented:
"FY2015 was a turnaround year. We achieved our
management guidance for the second consecutive year, led by our growth
drivers, and aided by the global launches of new products such as
ENTYVIO and NINLARO. Takeda will continue to deliver innovative new
medicines to patients, especially in our focused R&D therapeutic areas.
Takeda aims to relentlessly execute our strategic roadmap to deliver our
long-term aspiration, and will serve the needs of the patients, with the
best in class agility and innovation."
|
|||||||||
Key figures for the full |
year of FY2015 (April 2015 –March 2016) |
||||||||
FY 2014 | FY 2015 | Growth | |||||||
(billion yen) | Underlying2 | ||||||||
Revenue | 1,777.8 | 1,807.4 | +1.7% | +3.4% | |||||
Operating Profit | -129.3 | 130.8 | – | – | |||||
Core Earnings 1 | 288.3 | 292.4 | +1.4% | +8.1% | |||||
Net Profit 3 | -145.8 | 80.2 | – | – | |||||
EPS | -185 yen | 102 yen | – | – | |||||
Core EPS | 225 yen | 258 yen | +14.8% | +21.7% |
1 |
Core Earnings is calculated from operating profit by excluding the impact of exceptional items, such as purchase accounting, amortization and impairment loss of intangible assets, restructuring costs and major litigation costs. | |
2 |
Underlying performance aims at understanding the real performance of the business. Underlying Revenue, Underlying Core Earnings, and Underlying Core EPS exclude the same as above and adjusted for acquisitions/divestments and foreign exchange. | |
3 |
Attributable to the owners of the company | |
Underlying revenue growth was mainly driven by Takeda's Growth Drivers: Gastroenterology(GI), Oncology, and Central Nervous System (CNS) in addition to Emerging Markets. The Growth Drivers account for 52% of Takeda's revenue. GI revenue grew by +23.6% year-to-year, driven by ENTYVIO® . Oncology revenue increased by +1.0%, contributed by VELCADE® , ADCETRIS® and NINLARO® , which has shown an encouraging start in the U.S. since it was launched in December,. Oncology revenue excluding VELCADE royalties grew +4.4%. CNS revenue, including BRINTELLIX® , increased by +37.3%. Emerging Markets revenue grew by +4.8% year-to-year, led by Value Brands (branded generics and Over-The-Counter medicines), with steady growth in China (+11.1%), Russia (+6.2%) and Brazil (+5.7%). However, our future aspiration for growth in Emerging Markets remains strong, in high single digits. Performance in the U.S. (+12.4% year-to-year underlying revenue growth) also contributed to total revenue growth. In Japan, which remains under increasing generic pressure, underlying revenue declined -3.3% year-to-year, but AZILVA® and LOTRIGA® showed significant sales growth of +30.1% and +69.0%, respectively, year-to-year. In addition to these growing products, TAKECAB® and ZAFATEK® are expected to be key sales drivers in Japan after the lifting of the 2-week limit on the prescription period.
Consolidated operating profit was 130.8 billion yen, an increase of 260.1 billion yen compared to the previous year, which exceeded the raised forecast of 120 billion yen announced in February at the FY2015 3rd quarter earnings announcement. Selling, general and administrative expenses increased by 38.2 billion yen (+6.2%) compared to the previous year, mainly due to the increase in sales expenses related to new products in the U.S., but R&D expenses decreased by 36.2 billion yen (-9.5%). Amortization and impairment losses on intangible assets associated with products decreased by 51.3 billion yen (-29.1%), mainly due to 30.5 billion yen of COLCRYS® impairment loss being recognized in 2014 compared to an 8.6 billion yen impairment reversal in fiscal 2015. Other operating income decreased by 82.1 billion yen (-76.6%), mainly due to 53.8 billion yen of revaluation of COLCRYS® contingent consideration liability and 32.8 billion yen of the gains on sales of real estate being recognized in the previous year. Other operating expenses decreased by 277.8 billion yen (-86.2%), mainly due to 274.1 billion yen of loss on Actos litigation in the U.S. being recognized in the previous year.
Project Summit – a company-wide strategic initiative to increase efficiency – continued to produce results, with 30 billion yen of additional savings in FY2015, exceeding the full year target as a result of higher Procurement savings.
As part of its ongoing effort to improve R&D productivity, Takeda is focusing on its core therapeutic areas of Oncology, GI and CNS. Takeda will further strengthen its initiatives and commitment to lead innovation in medicines and provide innovative new drugs to patients around the world including in emerging markets.
FY2015 was positioned for Takeda as a year of turnaround to sustained growth, and Takeda sets the following management guidance for FY2016 as a year of strategic focus to sustain growth.
Management Guidance for FY2016 |
|||
Underlying Growth (%) | |||
Underlying Revenue | Mid-single digit | ||
Underlying Core Earnings | Low- to mid-teen | ||
Underlying Core EPS | Low- to mid-teen | ||
Dividend per Share | 180 yen |
Reported Forecast for FY2016 |
(change vs. FY2015 results) |
|||
billion yen | FY 2016 1 | Change | ||
Revenue | 1,720.0 | -4.8% | ||
R&D expenses | 325.0 | -6.0% | ||
Operating Profit | 135.0 | +3.2% | ||
Net Profit 2 | 88.0 | +9.8% | ||
EPS | 112 yen | +9.8% |
1 | The exchange rate assumptions for FY2016 are 1US$=110 yen and 1 euro=125 yen | |
2 | Attributable to the owners of the company | |
For more details on Takeda’s FY2015 full year results and other financial information, please visit http://www.takeda.com/investor-information/results/
About Takeda Pharmaceutical Company Limited
Takeda
Pharmaceutical Company Limited (TOKYO:4502
)
is a global, R&D-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating science
into life-changing medicines. Takeda focuses its research efforts on
oncology, gastroenterology and central nervous system therapeutic areas.
It also has specific development programs in specialty cardiovascular
diseases as well as late-stage candidates for vaccines. Takeda conducts
R&D both internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology, central
nervous system and gastroenterology, as well as its presence in emerging
markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160509006801/en/
Contact:
Takeda Pharmaceutical Company Limited
Investor Relations
Noriko
Higuchi, +81-(0)3-3278-2306
noriko.higuchi@takeda.com
or
Media
Relations
Japanese media
Tsuyoshi Tada, +81
(0)3-3278-2417
tsuyoshi.tada@takeda.com
or
Media
outside Japan
Jocelyn Gerst, +1-224-554-5542
jocelyn.gerst@takeda.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release
One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select
Bentley Systems Announces Winners of the 2025 Going Digital Awards17.10.2025 01:00:00 CEST | Press release
Company also recognizes key projects with Founders’ Honors, the Bentley-Envision winner for infrastructure sustainability, and the 2025 Bentley Educator of the Year (Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infr
Kinaxis Inc. to Host Third Quarter 2025 Financial Results Conference Call on November 6, 202516.10.2025 23:00:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its third quarter ended September 30, 2025. The call will be hosted on Thursday, November 6 at 8:30 a.m. Eastern Time by Bob Courteau, interim chief executive officer and chair, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the third quarter after the close of markets on Wednesday, November 5, 2025. CONFERENCE CALL DETAILSDATE: Thursday, November 6, 2025 TIME: 8:30 a.m. Eastern Time CALL REGISTRATION:https://registrations.events/direct/Q4I91416498WEBCAST:https://events.q4inc.com/attendee/875765587 (available for three months) Advance call registration Participants must register in advance for the live call. After registering, instructions on how to join the call will automatically be emailed, including dial-in informat
HCLTech and Zscaler Expand Partnership for AI-Powered Security and Network Transformation16.10.2025 20:13:00 CEST | Press release
HCLTech, a leading global technology company, and Zscaler™, a leader in cloud security, announced the expansion of their strategic partnership to provide AI-powered network transformation and enhanced zero-trust security services to enterprises worldwide. Under the new partnership scope, Zscaler's Zero Trust Exchange™ platform has been integrated with HCLTech's Cybersecurity Fusion Center (CSFC) platform. HCLTech’s AI capabilities, including SecOps and Responsible AI guardrails within HCLTech AI Force and AI Foundry are key to this partnership. This collaboration aims to enhance enterprise resilience and achieve business outcomes with a cloud-first, scalable security solution. HCLTech's Universal Managed Detection and Response (UMDR) services now integrate with Zscaler Internet Access™ (ZIA™), Zscaler Private Access™ (ZPA™) and other Zscaler components, providing context-rich threat detection, advanced analytics and faster response powered by AI and automation. Other key highlights of
Beyon Cyber and Haven Sign MoU to Launch Advanced AI-Powered SOC Capabilities in the UK and Worldwide16.10.2025 19:58:00 CEST | Press release
Beyon Cyber, part of the Beyon Group and the fastest growing cyber security company in the Middle East, has signed a Memorandum of Understanding (MoU) with Haven Cyber Technologies, a global cyber security services provider and a Microsoft Solutions Partner, through its UK-based subsidiary ITC Secure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016047852/en/ Beyon Cyber and Haven Sign MoU Under the MoU, Beyon Cyber and Haven will form a strategic partnership to revolutionize cyber security operations through the launch of advanced AI-driven Security Operations Centers (AI SOCs) in the United Kingdom and worldwide. As part of this collaboration, Haven will integrate Beyon Cyber’s cutting-edge AI SOC platform, Orryx AI, into its operations; harnessing the power of smart automation and agentic AI workflows to enhance threat detection, investigation, hunting, intelligence, and response. This partnership will enable both or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom